menu
Restore Vision Inc.
Tokyo
Healthcare
About
Restore Vision is a startup based in Japan aiming to develop a visual restoration gene therapy for retinitis pigmentosa. In collaboration with the Keio University School of Medicine, have a promising product with high sensitivity enabling patients to see even under low light conditions. It has proven to have competitive advantages at the pre-clinical stage, and are currently working towards an early clinical data acquisition.
Founders
Yusaku Katada CEO
Product
Gene therapy drug using adeno-associated viral vector by intravitreal administration. Irrespective of genotype of retinitis pigmentosa, it can be expected to have a semi-permanent therapeutic effect by single administration.
Achievement in alliance
Advisors with experience in ophthalmic AAV gene therapy drug development and CMC.